Industry Type: ALL Conventional Industry High-Tech Industry Service Industry Emerging Industry    Title:  

Biotechnology Services 2025-Jan Doc　#41539 Industry Report (condensed version) US$300 Government-backed initiatives to support the biomedical sector, coupled with enhanced regulatory compliance and the return of domestic medical capacity to pre-pandemic levels, are poised to optimize the operations of local clinical and preclinical CRO and CDMO firms. These favorable conditions are expected to propel continued growth in Taiwan's biotechnology services industry in 2025. Agricultural Biotechnology lndustry 2024-Nov Doc　#41173 Industry Report (condensed version) US$300 The agricultural biotechnology industry’s output value is expected to remain on a downward trend in Q4 2024, though the rate of decline is anticipated to moderate. Wind Power 2024-Jun Doc　#40498 Industry Report (condensed version) US$300 The annual growth rate of the industry's production value in 2024 is expected to be smaller than in 2023. However, the overall prosperity and development of the industry will continue to maintain a positive trend. China's Traditional Chinese Medicine Industry-Brief Report 2024-Jun Doc　#C_7043 Industry Report (condensed version) US$350 With the growing acceptance of specialty Chinese herbal medicines and their products both domestically and internationally, it is expected that China's traditional Chinese medicine manufacturing industry will resume growth in the second half of 2024. Traditional Chinese Medicine 2024-Apr Doc　#40060 Industry Report (condensed version) US$300 Given the elevated starting point from the preceding period, the industry landscape is poised to exhibit a degree of stagnation throughout the initial half of 2024. Biotechnology Services 2024-Mar Doc　#39854 Industry Report (condensed version) US$300 In 2024, Taiwan's biotechnology service industry is poised to navigate through a landscape marked by both challenges and opportunities. Fierce competition from established players in South Korea and China, delays in the clinical trial process for new drugs both domestically and abroad, and the high costs associated with obtaining key raw materials for manufacturing, suggest the industry's growth momentum may experience pressure. Food Biotechnology Industry 2024-Mar Doc　#39780 Industry Report (condensed version) US$300 The industry is poised to rebound and return to a trajectory of stable growth in the first half of 2024. Regenerative Medicine 2024-Feb Doc　#39781 Industry Report (condensed version) US$300 Despite the current challenges facing the launch of local cell therapy products in Taiwan and the intense competition faced by surgical suture materials from Chinese players in overseas markets, the domestic market for high-end tissue engineering biomedical material application products remains promising. This is largely due to concerted efforts by domestic players to consolidate and expand markets in China, ASEAN, and emerging markets such as the Middle East and Eastern Europe. Agricultural Biotechnology 2024-Jan Doc　#39507 Industry Report (condensed version) US$300 Taiwan's agricultural biotechnology industry is forecast to exhibit stable and sustained growth throughout the year 2024. Drug and Medical Supplies Distribution Industry 2023-Dec Doc　#39502 Industry Report (condensed version) US$300 The industry climate is expected to be slightly favorable in 2023.  First  Previous  Next  Last  In  1  /  8  Page  (Find  71  records)

Copyright (c) 2018 All Rights Reserved by
Taiwan Institute of Economic Research
Taiwan Industry Economics Services
Address: 4Fl., 16-8, Tehui St., Taipei, Taiwan
TEL: 886-2-25865000 ext469; FAX: 886-2-25935543